- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Avalere Analyst Reviews Future Change in Cancer Care Using Gene, Cell Therapies
Megan Olsen, MPH, principal at Avalere, discussed how gene and cell therapies can offer new treatment options for patients with cancer.
Transcript:
How do you anticipate gene therapies changing the face of treatments, especially in the oncology space?
Olsen: Yeah, that's a great question and one that we're starting to see play out right now as some of the earlier cell and gene therapies have entered the market.
Certainly, in the oncology space and more broadly, these are therapies that are 1-time administered and have a potentially more durable benefit over a longer period of time relative to more chronic therapies that are available today. In many cases, they are a treatment option for patients that have more limited options today, like maybe in the oncology space, where they have tried other treatment options that have failed. This is that next option that is available.
I think it's also important to acknowledge that as we think about some of the gene therapies, these are for some rare pediatric conditions in many cases where there are no or very limited treatment options available today. So, this is an entry of a really new treatment, which is exciting.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
